RU2006139424A - Вакцины - Google Patents
Вакцины Download PDFInfo
- Publication number
- RU2006139424A RU2006139424A RU2006139424/15A RU2006139424A RU2006139424A RU 2006139424 A RU2006139424 A RU 2006139424A RU 2006139424/15 A RU2006139424/15 A RU 2006139424/15A RU 2006139424 A RU2006139424 A RU 2006139424A RU 2006139424 A RU2006139424 A RU 2006139424A
- Authority
- RU
- Russia
- Prior art keywords
- vaccine composition
- adjuvant
- antigen
- toll
- subunit
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 19
- 239000000203 mixture Substances 0.000 claims 16
- 239000002671 adjuvant Substances 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 claims 7
- 108010079723 Shiga Toxin Proteins 0.000 claims 7
- 239000003970 toll like receptor agonist Substances 0.000 claims 7
- 239000002184 metal Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 1
- 229940123560 Toll-like receptor 4 agonist Drugs 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000008271 glucosaminides Chemical class 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0411411.2A GB0411411D0 (en) | 2004-05-21 | 2004-05-21 | Vaccines |
| GB0411411.2 | 2004-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006139424A true RU2006139424A (ru) | 2008-06-27 |
Family
ID=32607764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006139424/15A RU2006139424A (ru) | 2004-05-21 | 2005-05-19 | Вакцины |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080069832A1 (https=) |
| EP (1) | EP1761275A2 (https=) |
| JP (1) | JP2007538044A (https=) |
| KR (1) | KR20070029730A (https=) |
| CN (1) | CN1956729A (https=) |
| AU (1) | AU2005244615A1 (https=) |
| BR (1) | BRPI0511185A (https=) |
| CA (1) | CA2564778A1 (https=) |
| GB (1) | GB0411411D0 (https=) |
| IL (1) | IL178890A0 (https=) |
| MA (1) | MA28609B1 (https=) |
| MX (1) | MXPA06013386A (https=) |
| NO (1) | NO20065304L (https=) |
| RU (1) | RU2006139424A (https=) |
| WO (1) | WO2005112991A2 (https=) |
| ZA (1) | ZA200609500B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006104890A2 (en) | 2005-03-31 | 2006-10-05 | Glaxosmithkline Biologicals Sa | Vaccines against chlamydial infection |
| DK2457926T3 (da) | 2005-04-29 | 2015-01-05 | Glaxosmithkline Biolog Sa | Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion |
| JP2008540625A (ja) * | 2005-05-19 | 2008-11-20 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｅ．ｃｏｌｉ易熱性毒素のＢ−サブユニット、抗原およびアジュバントを含むワクチン組成物 |
| GB0524409D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
| GB0524408D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
| JP2009536653A (ja) * | 2006-05-09 | 2009-10-15 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | Ｈｉｖ−１免疫原性組成物 |
| EP1938836A1 (en) * | 2006-12-28 | 2008-07-02 | Universite Rene Descartes (Paris V) | Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells |
| JP5331105B2 (ja) | 2007-05-24 | 2013-10-30 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 凍結乾燥抗原組成物 |
| GB0724357D0 (en) * | 2007-12-14 | 2008-01-23 | Glaxosmithkline Biolog Sa | Method for preparing protein conjugates |
| WO2009126819A1 (en) * | 2008-04-09 | 2009-10-15 | Advanced Immune Therapeutics, Inc. | Methods for improving the bioactivity of therapeutic ige antibodies for the treatment of disease |
| AU2009344150B2 (en) * | 2009-04-09 | 2014-10-09 | Innavac Pty Ltd | Immunogenic composition and uses thereof |
| JP2012523379A (ja) * | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| GB0910045D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| TW201103980A (en) | 2009-07-08 | 2011-02-01 | Abbott Biologicals Bv | Viral vaccine and use thereof |
| DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| CN104688687A (zh) | 2009-12-03 | 2015-06-10 | 诺华股份有限公司 | 疫苗佐剂制备中的亲水过滤 |
| CL2012001399A1 (es) * | 2009-12-03 | 2013-03-08 | Novartis Ag | Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion. |
| DE102009056883B4 (de) * | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| EP2506834B1 (en) * | 2009-12-03 | 2016-03-02 | Novartis AG | Circulation of components during homogenization and microfluidization of emulsions |
| EP2618842B1 (en) | 2010-09-22 | 2019-04-24 | Ena Therapeutics Pty Ltd | Novel immunostimulatory method |
| CN106822883A (zh) | 2010-12-14 | 2017-06-13 | 葛兰素史密丝克莱恩生物有限公司 | 分枝杆菌抗原组合物 |
| CN102161998B (zh) * | 2011-01-14 | 2013-01-09 | 中国人民解放军军事医学科学院附属医院 | 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途 |
| GB201106357D0 (en) | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
| US20140234424A1 (en) * | 2011-07-22 | 2014-08-21 | Glaxosmithkline Biologicals Sa | Prame purification |
| EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
| EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| JP5931113B2 (ja) * | 2014-04-08 | 2016-06-08 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| TW201623329A (zh) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | 針對骨調素截斷變異體的疫苗及單株抗體暨其用途 |
| US10695424B2 (en) | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
| GB201621686D0 (en) * | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| KR101966346B1 (ko) * | 2017-01-13 | 2019-04-05 | 전북대학교 산학협력단 | 시가 독소 Stx2e를 제조하는 방법 및 이를 포함하는 부종병을 예방하기 위한 백신 조성물 |
| KR101987851B1 (ko) | 2017-04-28 | 2019-06-11 | 한국생명공학연구원 | 장출혈성대장균 유래의 시가독소 타입 1 B-subunit으로 유도된 노인성 황반변성(AMD) 동물모델 및 이를 이용한 스크리닝 방법 |
| BR112019025104A2 (pt) | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição |
| AU2018391325B2 (en) | 2017-12-21 | 2024-07-11 | Axelia Oncology Pty Ltd | Optimised compounds |
| CN108992667A (zh) * | 2018-08-09 | 2018-12-14 | 安徽智飞龙科马生物制药有限公司 | 一种带状疱疹疫苗及其制备方法、应用 |
| EP3886901A1 (en) * | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| EP3669890A1 (en) | 2018-12-18 | 2020-06-24 | Croda International PLC | Filamentous nanoparticles having vaccine adjuvant effect |
| MX2021015961A (es) | 2019-06-26 | 2022-03-22 | Ena Respiratory Pty Ltd | Moleculas novedosas. |
| EP4021407A1 (en) | 2019-08-30 | 2022-07-06 | GlaxoSmithKline Biologicals S.A. | Jet mixing lipid nanoparticle manufacturing process |
| CN111333734B (zh) * | 2020-03-31 | 2022-05-03 | 中国人民解放军军事科学院军事医学研究院 | 一种百日咳丝状血凝素融合蛋白及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2138997C (en) * | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| CA2218601A1 (en) * | 1995-03-24 | 1996-10-03 | Ophidian Pharmaceuticals, Inc. | Treatment for verotoxin-producing escherichia coli |
| GB9711990D0 (en) * | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| EP1078007B1 (en) * | 1998-05-15 | 2005-11-23 | Institut Curie | Verotoxin b subunit for immunization |
| PT1187629E (pt) * | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| EP1229045A1 (en) * | 2001-02-01 | 2002-08-07 | Institut Curie | Universal carrier for targeting molecules to Gb3 receptor expressing cells |
-
2004
- 2004-05-21 GB GBGB0411411.2A patent/GB0411411D0/en not_active Ceased
-
2005
- 2005-05-19 RU RU2006139424/15A patent/RU2006139424A/ru not_active Application Discontinuation
- 2005-05-19 KR KR1020067025212A patent/KR20070029730A/ko not_active Withdrawn
- 2005-05-19 MX MXPA06013386A patent/MXPA06013386A/es not_active Application Discontinuation
- 2005-05-19 BR BRPI0511185-4A patent/BRPI0511185A/pt not_active IP Right Cessation
- 2005-05-19 CN CNA2005800163224A patent/CN1956729A/zh active Pending
- 2005-05-19 EP EP05751697A patent/EP1761275A2/en not_active Withdrawn
- 2005-05-19 JP JP2007517101A patent/JP2007538044A/ja active Pending
- 2005-05-19 US US11/569,177 patent/US20080069832A1/en not_active Abandoned
- 2005-05-19 AU AU2005244615A patent/AU2005244615A1/en not_active Abandoned
- 2005-05-19 WO PCT/EP2005/005555 patent/WO2005112991A2/en not_active Ceased
- 2005-05-19 CA CA002564778A patent/CA2564778A1/en not_active Abandoned
-
2006
- 2006-10-26 IL IL178890A patent/IL178890A0/en unknown
- 2006-11-15 ZA ZA200609500A patent/ZA200609500B/xx unknown
- 2006-11-20 NO NO20065304A patent/NO20065304L/no not_active Application Discontinuation
- 2006-11-28 MA MA29491A patent/MA28609B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1956729A (zh) | 2007-05-02 |
| MXPA06013386A (es) | 2007-01-23 |
| IL178890A0 (en) | 2007-03-08 |
| AU2005244615A1 (en) | 2005-12-01 |
| MA28609B1 (fr) | 2007-05-02 |
| KR20070029730A (ko) | 2007-03-14 |
| ZA200609500B (en) | 2008-02-27 |
| WO2005112991A2 (en) | 2005-12-01 |
| US20080069832A1 (en) | 2008-03-20 |
| EP1761275A2 (en) | 2007-03-14 |
| JP2007538044A (ja) | 2007-12-27 |
| BRPI0511185A (pt) | 2007-12-04 |
| WO2005112991A3 (en) | 2006-03-30 |
| GB0411411D0 (en) | 2004-06-23 |
| NO20065304L (no) | 2006-11-20 |
| CA2564778A1 (en) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006139424A (ru) | Вакцины | |
| Pedersen et al. | Immunocorrelates of CAF family adjuvants | |
| García et al. | An overview of adjuvant formulations and delivery systems | |
| US10730915B2 (en) | Flagellin-based agents and uses including effective vaccination | |
| JP2007538044A5 (https=) | ||
| Duthie et al. | Use of defined TLR ligands as adjuvants within human vaccines | |
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| Lahiri et al. | Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond | |
| Mbow et al. | New adjuvants for human vaccines | |
| Tagliabue et al. | Vaccine adjuvants: the dream becomes real | |
| JP4731475B2 (ja) | 毒性の低いＱｕｉｌＡ画分およびその使用 | |
| Stills | Polyclonal antibody production | |
| BRPI0414381A (pt) | composição de adjuvante, composição ou composições imunogênica(s), composição de vacina, processo para a fabricação de uma composição imunogênica, composição ou composições farmacêutica(s), kit, métodos para tratar um paciente que sofre de, ou que é suscetìvel a, um tumor, para incrementar uma resposta imune de um mamìfero a um antìgeno e para suscitar uma resposta imune em m mamìfero contra um estado de doença, usos de uma imidazoquinolina ou derivado da mesma e gm-csf e dos componentes | |
| TW200722101A (en) | Novel composition | |
| RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
| Sanders et al. | Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines | |
| MX2009000660A (es) | Vacuna de influenza. | |
| Lingnau et al. | Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| Akache et al. | Adjuvants: engineering protective immune responses in human and veterinary vaccines | |
| Wang et al. | Immune responses to varicella-zoster virus glycoprotein E formulated with poly (lactic-co-glycolic acid) nanoparticles and nucleic acid adjuvants in mice | |
| JP2019515005A (ja) | 水酸化アルミニウムゲル−塩化ナトリウム複合免疫学的アジュバント、並びにその調製方法及びその使用 | |
| Garg et al. | Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain | |
| Chua et al. | Opinion: making inactivated and subunit-based vaccines work | |
| Del Giudice | New carriers and adjuvants in the development of vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100602 |